ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Reaffirmed by HC Wainwright

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $9.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 171.90% from the stock’s previous close.

ImmunoPrecise Antibodies Price Performance

Shares of IPA opened at $3.31 on Friday. The company has a market cap of $82.52 million, a P/E ratio of -3.85 and a beta of 0.60. The stock has a fifty day moving average price of $4.33 and a 200 day moving average price of $4.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.10 and a quick ratio of 2.89. ImmunoPrecise Antibodies has a 12 month low of $3.17 and a 12 month high of $6.50.

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) last issued its quarterly earnings data on Thursday, December 15th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.09). ImmunoPrecise Antibodies had a negative return on equity of 39.89% and a negative net margin of 126.00%. The company had revenue of $3.89 million for the quarter, compared to the consensus estimate of $3.91 million. On average, research analysts forecast that ImmunoPrecise Antibodies will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IPA. Bank of America Corp DE boosted its position in ImmunoPrecise Antibodies by 1,849.1% during the 1st quarter. Bank of America Corp DE now owns 57,517 shares of the company’s stock worth $295,000 after acquiring an additional 54,566 shares during the period. Bank of Montreal Can lifted its holdings in shares of ImmunoPrecise Antibodies by 62.7% in the first quarter. Bank of Montreal Can now owns 140,454 shares of the company’s stock valued at $718,000 after buying an additional 54,145 shares during the period. Cibc World Market Inc. acquired a new stake in shares of ImmunoPrecise Antibodies in the second quarter valued at $183,000. Ingalls & Snyder LLC lifted its holdings in shares of ImmunoPrecise Antibodies by 2.9% in the third quarter. Ingalls & Snyder LLC now owns 967,090 shares of the company’s stock valued at $3,859,000 after buying an additional 27,615 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of ImmunoPrecise Antibodies in the first quarter valued at $67,000. Institutional investors and hedge funds own 5.68% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

(Get Rating)

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes.